<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04098744</url>
  </required_header>
  <id_info>
    <org_study_id>ART-CIN IIB</org_study_id>
    <secondary_id>2020 0237</secondary_id>
    <secondary_id>20 1148</secondary_id>
    <nct_id>NCT04098744</nct_id>
  </id_info>
  <brief_title>Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)</brief_title>
  <acronym>ART-CIN_IIB</acronym>
  <official_title>A Phase II Double Blind, Placebo-controlled, Randomized Trial of Artesunate Vaginal Inserts for the Treatment of Patients With Cervical Intraepithelial Neoplasia (CIN2/3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Frantz Viral Therapeutics, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amarex Clinical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Harris Health System (L.B.J. Hospital)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Frantz Viral Therapeutics, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II double blind, placebo-controlled, randomized study of Artesunate vaginal&#xD;
      inserts for the treatment of women who have cervical high grade intraepithelial neoplasia&#xD;
      (CIN2/3).&#xD;
&#xD;
      Participants who receive placebo in this study have the option to receive active drug&#xD;
      (artesunate) after their week 15 colposcopy visit.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible participants in this study are randomized to receive either artesunate or placebo&#xD;
      vaginal inserts for the treatment of CIN2/3. Both groups receive three 5-day cycles of the&#xD;
      respective drug, at weeks 0, 2, and 4. Dosing visits can be done as telehealth visits&#xD;
      (medication is mailed to the patient's home). Participants are followed closely with&#xD;
      colposcopies at weeks 6, 15, and 28. After the week 15 colposcopy visit the investigator is&#xD;
      unblinded. Participants in the placebo group who still have CIN2/3 have the option to start&#xD;
      treatment with artesunate within 4 weeks. Participants in the artesunate treatment who still&#xD;
      have CIN2/3 at the week 15 visit, will undergo standard of care surgical treatment (LEEP or&#xD;
      cold knife conization) within 6 weeks.&#xD;
&#xD;
      Primary Objective: To evaluate the histopathologic regression after three 5-day cycles of&#xD;
      artesunate vaginal inserts in adult females with biopsy-proven HPV-associated CIN 2/3.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  To evaluate the safety of artesunate vaginal inserts for the treatment of CIN2/3&#xD;
&#xD;
        -  To evaluate the viral clearance after three 5-day cycles of artesunate vaginal inserts&#xD;
           in adult females with biopsy-proven HPV-associated CIN 2/3.&#xD;
&#xD;
        -  To evaluate histopathologic regression after the week 15 time point&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 9, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants with histologic regression by week 15</measure>
    <time_frame>15 weeks</time_frame>
    <description>Number of participants who undergo histologic regression to cervical intraepithelial neoplasia (CIN) 1 or less by week 15, following 3 cycles of artesunate vaginal inserts, as determined by biopsy histopathologic analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants who have achieved clearance of detectable human papilloma virus (HPV) by week 15</measure>
    <time_frame>15 weeks</time_frame>
    <description>Number of participants who had HPV strains detected at study entry which become undetectable within the study window (15 weeks)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with histologic regression after week 15</measure>
    <time_frame>21 weeks</time_frame>
    <description>Number of participants who undergo histologic regression to cervical intraepithelial neoplasia (CIN) 1 or less after week 15 following 3 cycles of artesunate vaginal inserts, as determined by biopsy histopathologic analysis</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of participants with Treatment-Emergent Adverse Events (TEAE)</measure>
    <time_frame>28 weeks</time_frame>
    <description>Number of participants who had adverse events, as defined by CTCAE v5.0, related to the study intervention</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants who withdrew from the study due to TEAEs</measure>
    <time_frame>28 weeks</time_frame>
    <description>Number of participants who were withdrawn from the study due to adverse events related to the study drug</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>CIN 2/3</condition>
  <condition>HPV Infection</condition>
  <condition>Pre-Cancerous Dysplasia</condition>
  <condition>Cervical Dysplasia</condition>
  <condition>HPV Related Disease</condition>
  <arm_group>
    <arm_group_label>Artesunate vaginal insert</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive three 5-day cycles of artesunate vaginal inserts, 200mg/day, at week 0, week 2, week 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo vaginal inserts</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive three 5-day cycles of placebo vaginal inserts, at week 0, week 2, and week 4. Unblinding will take place at week 15. Participants who do not have histologic regression at week 15 will have the opportunity to cross over to the experimental arm, and start treatment with artesunate vaginal inserts within 4 weeks of the week 15 visit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Artesunate vaginal insert</intervention_name>
    <description>Artesunate formulated as vaginal inserts, 200mg</description>
    <arm_group_label>Artesunate vaginal insert</arm_group_label>
    <other_name>Artesunic acid</other_name>
    <other_name>DHA</other_name>
    <other_name>artemisinin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo vaginal insert</intervention_name>
    <description>Placebo for artesunate vaginal inserts</description>
    <arm_group_label>Placebo vaginal inserts</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult females age ≥ 25 years&#xD;
&#xD;
          -  Capable of informed consent&#xD;
&#xD;
          -  Any HPV genotype detectable by DNA test/HPV genotyping&#xD;
&#xD;
          -  Colposcopically-directed, histologically confirmed tissue diagnosis of either CIN2,&#xD;
             CIN3, or CIN2/3&#xD;
&#xD;
          -  Women of childbearing potential agree to use birth control through week 28 of the&#xD;
             study.&#xD;
&#xD;
          -  Weight ≥ 50kg&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant and nursing women&#xD;
&#xD;
          -  Active autoimmune disease&#xD;
&#xD;
          -  Taking immunosuppressive medication&#xD;
&#xD;
          -  HIV seropositivity&#xD;
&#xD;
          -  Immunocompromised subjects&#xD;
&#xD;
          -  Evidence of concurrent cervical adenocarcinoma in situ&#xD;
&#xD;
          -  Concurrent malignancy except for nonmelanoma skin lesions, because treatment for other&#xD;
             cancers have systemic effects&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>This study is for women only as it is a treatment for cervical intraepithelial neoplasia (CIN2/3)</gender_description>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mihaela Plesa, BA, CCRP</last_name>
    <phone>440-255-1155</phone>
    <phone_ext>100</phone_ext>
    <email>mplesa@frantzgroup.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ahmad Bayat, MD</last_name>
    <phone>(301) 956-2523</phone>
    <email>ahmadb@amarexcro.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cleveland Clinic Fairview Hospital</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna White</last_name>
      <phone>216-445-8090</phone>
      <email>whited11@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Megan Park</last_name>
      <phone>216-445-8090</phone>
      <email>parkm2@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>Chad Michener, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mariam AlHilli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven Waggonner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert DeBernardo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roberto Vargas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna White</last_name>
      <phone>216-445-8090</phone>
      <email>whited11@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Megan Park</last_name>
      <phone>216-445-8090</phone>
      <email>parkm2@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>Chad Michener, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mariam AlHilli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven Waggonner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert DeBernardo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roberto Vargas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hillcrest Hospital</name>
      <address>
        <city>Mayfield Heights</city>
        <state>Ohio</state>
        <zip>44124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna White</last_name>
      <phone>216-445-8090</phone>
      <email>whited11@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Megan Park</last_name>
      <phone>216-445-8090</phone>
      <email>parkm2@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>Chad Michener, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mariam AlHilli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven Waggonner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert DeBernardo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roberto Vargas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Harris Health System (L.B.J Hospital)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77026</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Gallegos</last_name>
      <phone>713-563-4580</phone>
      <email>jrgalleg@mdanderson.org</email>
    </contact>
    <contact_backup>
      <last_name>Cindy Melendez</last_name>
      <phone>713-563-4582</phone>
      <email>cvmelend@mdanderson.org</email>
    </contact_backup>
    <investigator>
      <last_name>Andrea Milbourne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kathleen Schmeler, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas, M.D. Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Gallegos</last_name>
      <phone>713-563-4580</phone>
      <email>jrgalleg@mdanderson.org</email>
    </contact>
    <contact_backup>
      <last_name>Cindy Melendez</last_name>
      <phone>713-563-4582</phone>
      <email>cvmelend@mdanderson.org</email>
    </contact_backup>
    <investigator>
      <last_name>Andrea Milbourne, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kathleen Schmeler, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>September 19, 2019</study_first_submitted>
  <study_first_submitted_qc>September 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2019</study_first_posted>
  <last_update_submitted>June 28, 2021</last_update_submitted>
  <last_update_submitted_qc>June 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>treatment study</keyword>
  <keyword>cancer prevention</keyword>
  <keyword>non-surgical</keyword>
  <keyword>HPV related disease</keyword>
  <keyword>CIN</keyword>
  <keyword>topical treatment</keyword>
  <keyword>vaginal inserts</keyword>
  <keyword>artesunate</keyword>
  <keyword>artemisinin</keyword>
  <keyword>non-invasive</keyword>
  <keyword>high risk HPV</keyword>
  <keyword>vaginal suppository</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Papillomavirus Infections</mesh_term>
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
    <mesh_term>Uterine Cervical Dysplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Artesunate</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
    <mesh_term>Artemisinin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

